Oramed Pharmaceuticals, Inc. (ORMP) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Oramed Pharmaceuticals, Inc.

Protalix Biotherapeutics, Inc.

Gamida Cell Ltd.

Nektar Therapeutics

Esperion Therapeutics, Inc.

Annexon, Inc.

Talaris Therapeutics, Inc.

Inovio Pharmaceuticals, Inc.

Reviva Pharmaceuticals Holdings, Inc.

Calidi Biotherapeutics, Inc.

Ocean Biomedical, Inc.

Why is Oramed Pharmaceuticals, Inc. ?

With a growth in Net Profit of 264.2%, the company declared Outstanding results in Sep 25

The company has declared positive results in Jan 70 after 3 consecutive negative quarters
ROCE(HY) Highest at 24.38%
PRE-TAX PROFIT(Q) Highest at USD 39.49 MM
NET PROFIT(Q) Highest at USD 32.15 MM

With ROE of 10.05%, it has a very attractive valuation with a 0.69 Price to Book Value

Over the past year, while the stock has generated a return of 46.15%, its profits have risen by 365.2% ; the PEG ratio of the company is 0

High Institutional Holdings at 20.05%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating Performance

The stock has generated a return of 46.15% in the last 1 year, much higher than market (S&P 500) returns of 13.68%

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Oramed Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Oramed Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Oramed Pharmaceuticals, Inc.

49.57%

1.26

48.09%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-5.90%

EBIT Growth (5y)

-3.73%

EBIT to Interest (avg)

-19.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.93

Sales to Capital Employed (avg)

0.01

Tax Ratio

7.30%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

20.05%

ROCE (avg)

ROE (avg)

2.34%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.69

EV to EBIT

-0.38

EV to EBITDA

-0.38

EV to Capital Employed

0.07

EV to Sales

2.45

PEG Ratio

0.02

Dividend Yield

0.72%

ROCE (Latest)

-18.89%

ROE (Latest)

10.05%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

31What is working for the Company

ROCE(HY)

Highest at 24.38%

PRE-TAX PROFIT(Q)

Highest at USD 39.49 MM

NET PROFIT(Q)

Highest at USD 32.15 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

NET SALES(9M)

Higher at USD 2 MM

OPERATING PROFIT(Q)

Highest at USD -2.4 MM

EPS(Q)

Highest at USD 1.13

-1What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at -65.83 %

Here's what is working for Oramed Pharmaceuticals, Inc.

Net Sales

At USD 2 MM has Grown at inf%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Pre-Tax Profit

At USD 39.49 MM has Grown at 638.09%

over average net sales of the previous four periods of USD -7.34 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 32.15 MM has Grown at 510.82%

over average net sales of the previous four periods of USD -7.83 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Pre-Tax Profit

Highest at USD 39.49 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD 32.15 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Profit

Highest at USD -2.4 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

EPS

Highest at USD 1.13

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Net Sales

Higher at USD 2 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Oramed Pharmaceuticals, Inc.

Debt-Equity Ratio

Highest at -65.83 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio